Spots Global Cancer Trial Database for sclc
Every month we try and update this database with for sclc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer | NCT01591512 | Small Cell Lung... | 18 Years - | Fujirebio Diagnostics, Inc. | ||
| Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC) | NCT00452634 | Small Cell Lung... | Irinotecan Cisplatin Simvastatin | 18 Years - | National Cancer Center, Korea | |
| Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer | NCT05797493 | Small Cell Lung... | Atezolizumab | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | NCT06131840 | Colorectal Neop... Carcinoma, Non-... Stomach Neoplas... Pancreatic Duct... Gastroesophagea... Small Cell Lung... | SGN-CEACAM5C | 18 Years - | Seagen Inc. | |
| Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy | NCT03703297 | Small Cell Lung... | Durvalumab Tremelimumab Placebo | 18 Years - 130 Years | AstraZeneca | |
| A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | NCT06095505 | Small Cell Lung... | Alisertib | 18 Years - | Puma Biotechnology, Inc. | |
| TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | NCT05655598 | Advanced Breast... Treatment-Refra... Retinoblastoma ... SCLC Soft Tissue Sar... Endometrial Can... Bladder Cancer | Palbociclib Ora... TAS-116 TAS-116 TAS-116 | 18 Years - | Brown University | |
| An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer | NCT06179069 | SCLC | ZL-1310 | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer | NCT05903092 | Small Cell Lung... SCLC Extensive Stage... | Durvalumab Monalizumab Carboplatin or ... Etoposide | 18 Years - | Hoosier Cancer Research Network | |
| Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer | NCT02748889 | Small Cell Lung... | Carboplatin Etoposide MPDL3280A | 18 Years - | Georgetown University | |
| A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy | NCT00447421 | Small Cell Lung... Carcinoma, Smal... SCLC | pemetrexed cisplatin radiation | 18 Years - | Eli Lilly and Company | |
| A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | NCT05026593 | SCLC | Carboplatin Cisplatin Etoposide Sintilimab IBI110 | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | NCT04590781 | Merkel Cell Car... Small Cell Lung... | XmAb18087 XmAb18087 ± Pem... | 18 Years - | Xencor, Inc. | |
| Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer | NCT00755157 | Small Cell Lung... | Docetaxel Bevacizumab | 18 Years - | University Hospital of Crete | |
| Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy | NCT03703297 | Small Cell Lung... | Durvalumab Tremelimumab Placebo | 18 Years - 130 Years | AstraZeneca | |
| A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | NCT01829971 | Primary Liver C... SCLC Lymphoma Melanoma Multiple Myelom... Renal Cell Carc... NSCLC | MRX34 | 18 Years - | Mirna Therapeutics, Inc. | |
| Study of AZD2811 + Durvalumab in ES-SCLC | NCT04745689 | Small-Cell Lung... | Durvalumab AZD2811 Carboplatin Cisplatin Etoposide | 18 Years - 130 Years | AstraZeneca | |
| Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer | NCT00755157 | Small Cell Lung... | Docetaxel Bevacizumab | 18 Years - | University Hospital of Crete | |
| A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies | NCT00445198 | Small Cell Lung... Small Cell Lung... | ABT-263 | 18 Years - | AbbVie | |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | NCT04032704 | Small Cell Lung... Non-small Cell ... Non-small Cell ... Head and Neck S... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Prostate Cancer Melanoma | ladiratuzumab v... pembrolizumab | 18 Years - | Seagen Inc. | |
| Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy. | NCT04285866 | Small Cell Lung... | Durvalumab | 18 Years - | Fundación GECP | |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | NCT02611024 | Advanced Solid ... Glioblastoma Soft Tissue Sar... Endometrial Car... Epithelial Ovar... Mesothelioma Gastroenteropan... SCLC Gastric Carcino... Pancreatic Aden... Colorectal Carc... Neuroendocrine ... | Lurbinectedin Irinotecan | 18 Years - | PharmaMar | |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | NCT04032704 | Small Cell Lung... Non-small Cell ... Non-small Cell ... Head and Neck S... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Prostate Cancer Melanoma | ladiratuzumab v... pembrolizumab | 18 Years - | Seagen Inc. | |
| Lung Cancer Registry for Lung Cancer Patients | NCT03276429 | Lung Cancer | 18 Years - | Oncology Center of Biochemical Education And Research | ||
| Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma | NCT00483509 | Small Cell Lung... | NGR-hTNF Doxorubicin | 18 Years - | AGC Biologics S.p.A. | |
| Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer | NCT04750239 | SCLC | Nivatrotamab | 18 Years - | Y-mAbs Therapeutics | |
| Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy | NCT05703269 | NSCLC Renal Cell Carc... Breast Carcinom... Melanoma Brain Metastase... Non-small Cell ... SCLC Small-cell Lung... | single fraction... fractionated st... | 18 Years - | Wake Forest University Health Sciences | |
| A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) | NCT04834778 | Renal Cell Carc... Gastric Cancer Metastatic Brea... Small-cell Lung... Other Solid Tum... | HC-5404-FU | 18 Years - | HiberCell, Inc. | |
| Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer | NCT05740566 | Small Cell Lung... | Tarlatamab Lurbinectedin Topotecan Amrubicin | 18 Years - | Amgen | |
| A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | NCT03575793 | Lung Cancer SCLC | Nivolumab Plinabulin Ipilimumab | 18 Years - | Big Ten Cancer Research Consortium | |
| Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | NCT04902872 | Solid Tumor, Ad... Epithelial Ovar... Small Cell Lung... Breast Cancer Colorectal Canc... Pancreas Cancer Appendix Cancer Non-small Cell ... Gastric Cancer Esophagus Cance... Urothelial Carc... Sarcoma | CBX-12 | 18 Years - | Cybrexa Therapeutics | |
| A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC | NCT05879068 | SCLC | PM8002 Paclitaxel | 18 Years - | Biotheus Inc. | |
| TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | NCT05655598 | Advanced Breast... Treatment-Refra... Retinoblastoma ... SCLC Soft Tissue Sar... Endometrial Can... Bladder Cancer | Palbociclib Ora... TAS-116 TAS-116 TAS-116 | 18 Years - | Brown University | |
| PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | NCT03460977 | Castration Resi... Small Cell Lung... Follicular Lymp... | PF-06821497 | 18 Years - | Pfizer | |
| Lung Cancer Registry for Lung Cancer Patients | NCT03276429 | Lung Cancer | 18 Years - | Oncology Center of Biochemical Education And Research | ||
| Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED) | NCT00812266 | Extensive Disea... First-Line Small Cell Lung... | topotecan + cis... Etoposide + car... | 18 Years - | Danish Oncological Lung Cancer Group | |
| Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer | NCT02769832 | Small Cell Lung... | Nab-paclitaxel Gemcitabine | 18 Years - 99 Years | University of Iowa | |
| Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer | NCT01441349 | Small Cell Lung... | IP chemotherapy IP chemotherapy... | 18 Years - | National Cancer Center, Korea | |
| Pharmacogenomics IND EXEMPT SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms | NCT01064466 | Small Cell Lung... | ETOPOSIDE - Usu... ETOPOSIDE - Stu... | 22 Years - 75 Years | Medicine Invention Design, Inc | |
| Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer | NCT04684017 | SCLC Anlotinib | Anlotinib hydro... Etoposide Carboplatin | 18 Years - 75 Years | Shanghai Chest Hospital | |
| BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors | NCT00346385 | Ovarian Cancer Merkel Cell Car... SCLC | BB-10901 | 18 Years - | ImmunoGen, Inc. | |
| A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE) | NCT00403403 | Small Cell Lung... | Bevacizumab Chemotherapy Placebo | 18 Years - | Genentech, Inc. | |
| Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS) | NCT06116019 | Prostate Cancer Head and Neck C... NSCLC SCLC Esophageal Canc... Bladder Cancer Rectum Cancer Cervix Cancer Other Carcinoma | Online adaptive... | 18 Years - | Charite University, Berlin, Germany | |
| Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC) | NCT01166191 | Stage I-III Sma... | Radiotherapy | 18 Years - | Maastricht Radiation Oncology | |
| Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy | NCT02446704 | Small Cell Lung... | Olaparib Temozolomide | 18 Years - | Massachusetts General Hospital | |
| Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer | NCT00923884 | Carcinoma, Non-... Carcinoma, Smal... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer | NCT01784107 | Small Cell Lung... | Belotecan and I... | 18 Years - | Gachon University Gil Medical Center | |
| Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC | NCT03177291 | Lung Cancer Non Small Cell ... Advanced Cancer Metastatic Lung... Squamous Cell L... Non-Squamous No... | Pirfenidone Carboplatin Paclitaxel Pemetrexed | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | NCT00926640 | Carcinoma Neuro... Small Cell Lung... Malignant Epith... | Belinostat Cisplatin Etoposide | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC) | NCT00916669 | Small Cell Lung... | Etoposide Cisplatin enoxaparin sodi... | 18 Years - | Massachusetts General Hospital | |
| Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | NCT04590781 | Merkel Cell Car... Small Cell Lung... | XmAb18087 XmAb18087 ± Pem... | 18 Years - | Xencor, Inc. | |
| Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | NCT02963090 | Small Cell Lung... | Topotecan Pembrolizumab | 18 Years - | Alliance Foundation Trials, LLC. | |
| Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer | NCT02748889 | Small Cell Lung... | Carboplatin Etoposide MPDL3280A | 18 Years - | Georgetown University | |
| Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer | NCT01441349 | Small Cell Lung... | IP chemotherapy IP chemotherapy... | 18 Years - | National Cancer Center, Korea | |
| Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease | NCT02046733 | Limited Stage S... Small Cell Lung... | Ipilimumab Nivolumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| Study of AZD2811 + Durvalumab in ES-SCLC | NCT04745689 | Small-Cell Lung... | Durvalumab AZD2811 Carboplatin Cisplatin Etoposide | 18 Years - 130 Years | AstraZeneca | |
| Accelerated Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LS-SCLC | NCT02990780 | SCLC | Conventionally ... Accelerated hyp... | 18 Years - 70 Years | Shanghai Chest Hospital | |
| A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer | NCT01076504 | Extensive-Stage... | Amrubicin Carboplatin Pegfilgrastim | 18 Years - | SCRI Development Innovations, LLC | |
| A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer | NCT00977561 | Small Cell Lung... | figitumumab Cisplatin (Or C... Etoposide Cisplatin (Or C... Etoposide | 18 Years - | Pfizer | |
| Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment | NCT03244904 | SCLC | 18 Years - 70 Years | Fujian Cancer Hospital | ||
| Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma | NCT03958045 | Small Cell Lung... | Rucaparib and N... | 18 Years - | University of Kentucky | |
| Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy | NCT02446704 | Small Cell Lung... | Olaparib Temozolomide | 18 Years - | Massachusetts General Hospital | |
| A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors | NCT05268666 | Locally Advance... Metastatic Soli... | JBI-802 | 18 Years - | Jubilant Therapeutics Inc. | |
| Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer | NCT04750239 | SCLC | Nivatrotamab | 18 Years - | Y-mAbs Therapeutics | |
| Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC) | NCT01210131 | Small Cell Lung... | [18F]HX4 | 18 Years - | Maastricht Radiation Oncology | |
| Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer | NCT02748889 | Small Cell Lung... | Carboplatin Etoposide MPDL3280A | 18 Years - | Georgetown University | |
| Radiomics: a Study of Outcome in Lung Cancer | NCT01302626 | Lung Cancer | 18 Years - | Maastricht Radiation Oncology | ||
| A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | NCT02922764 | Endometrial Can... Endometrial Can... Lung Cancer Rec... Lung Cancer Non-small Cell ... Non-small Cell ... | RGX-104 Ipilimumab Docetaxel Pembrolizumab Carboplatin Pemetrexed | 18 Years - | Inspirna, Inc. | |
| Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease | NCT04462276 | Small Cell Lung... Thoracic Radiot... | Atezolizumab thoracic radiot... | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation | NCT00522639 | Lung Cancer SCLC NSCLC | 18F-deoxyglucos... | 18 Years - | Maastricht Radiation Oncology | |
| Phase I Study of IV DOTAP: Cholesterol-Fus1 in Non-Small-Cell Lung Cancer | NCT00059605 | Lung Cancer | DOTAP:Chol-fus1 | - | M.D. Anderson Cancer Center | |
| A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | NCT00926640 | Carcinoma Neuro... Small Cell Lung... Malignant Epith... | Belinostat Cisplatin Etoposide | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy | NCT02446704 | Small Cell Lung... | Olaparib Temozolomide | 18 Years - | Massachusetts General Hospital | |
| GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | NCT04060342 | Pancreatic Aden... Esophageal Aden... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Triple Negative... Castration-resi... Microsatellite ... Non-small Cell ... Small-cell Lung... Head and Neck S... Urothelial Carc... Renal Cell Carc... Hepatocellular ... | GB1275 nab-paclitaxel ... pembrolizumab | 18 Years - | Gossamer Bio Inc. | |
| Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation | NCT00522639 | Lung Cancer SCLC NSCLC | 18F-deoxyglucos... | 18 Years - | Maastricht Radiation Oncology | |
| A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE) | NCT00403403 | Small Cell Lung... | Bevacizumab Chemotherapy Placebo | 18 Years - | Genentech, Inc. | |
| GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | NCT04060342 | Pancreatic Aden... Esophageal Aden... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Triple Negative... Castration-resi... Microsatellite ... Non-small Cell ... Small-cell Lung... Head and Neck S... Urothelial Carc... Renal Cell Carc... Hepatocellular ... | GB1275 nab-paclitaxel ... pembrolizumab | 18 Years - | Gossamer Bio Inc. | |
| Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients | NCT00466466 | Small-Cell Lung... | Everolimus | 18 Years - | Novartis | |
| Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection | NCT06021483 | SCLC | 19 Years - | Boryung Pharmaceutical Co., Ltd | ||
| Study of Oral MRT-2359 in Selected Cancer Patients | NCT05546268 | NSCLC SCLC High Grade Neur... DLBCL L-MYC and N-MYC... NSCLC With High... HR-positive, HE... Prostate Cancer | Oral MRT-2359 Oral MRT-2359 Oral MRT-2359 Oral MRT-2359 Oral MRT-2359 Oral MRT-2359 | 18 Years - | Monte Rosa Therapeutics, Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
